SB Adani Family Trust, a promoter entity, has recently conducted open market transactions to sell 1.8 crore equity shares, equivalent to a 1.57% stake in the company. The shares were sold at an average price of Rs 2,300 per share, resulting in a total value of Rs 4,140 crore. Prior to the stake sale, Gautam S Adani and Rajesh S Adani, on behalf of SB Adani Family Trust, held 59.13 crore shares, representing a 51.87% stake in the company as of March 2023.
Housing Development Finance Corporation (HDFC), the promoter of HDFC Life Insurance Company, has acquired an additional 1.65 crore equity shares, representing a 0.77% stake in the insurance company. The purchase was made through open market transactions at an average price of Rs 674.87 per share, resulting in a total investment of Rs 1,118.84 crore.
Tata Communications has announced its plan to acquire Kaleyra Inc, a US-based company with subsidiaries in various countries including the United States of America, Italy, India, UAE, Germany, UK, Dominican Republic, Mexico, Africa, and Canada. Kaleyra specializes in providing mobile communication services. This strategic acquisition will enable Tata Communications to expand its CPaaS (Communication Platform as a Service) business globally. The transaction is anticipated to be completed within a timeframe of 6-9 months, with the purchase consideration of $7.25 per share to be made in cash. The total consideration for the acquisition is expected to amount to approximately $100 million.
Goldman Sachs Trust II – Goldman Sachs GQG Partners International Opportunities Fund has recently acquired an additional 1.19 crore equity shares, representing a 0.75% stake in Adani Green Energy. The purchase was made through open market transactions at an average price of Rs 920.05 per share. However, during the same period, Infinite Trade and Investment Ltd, a promoter group entity, sold 4.6 crore shares, equivalent to a 2.9% stake in the company, at an average price of Rs 920.03 per share.
The pharmaceutical company has been granted tentative approval by the US Food and Drug Administration (USFDA) for its Palbociclib tablets, which are offered in strengths of 75 mg, 100 mg, and 125 mg. Palbociclib is a medication used for the treatment of a specific type of breast cancer. The manufacturing of this product will take place at the company’s formulation manufacturing facility located in SEZ, Ahmedabad. According to IQVIA MAT data from April 2023, Palbociclib recorded annual sales of $3.3 billion in the United States.
After a major sell-off earlier in the week, Adani Group stocks, led by Ambuja Cements…
A sharp rally in financial stocks and encouraging US labor market data fueled the uptrend.…
PM Narendra Modi held 31 bilateral meetings and discussions during his visit to Nigeria, Brazil,…
These words were added during the 42nd Amendment in 1976, under the tenure of Prime…
During the hearing, the Supreme Court clarified that the six MLAs removed as Chief Parliamentary…
Bumrah’s 4-17, backed by Mohammed Siraj and debutant Harshit Rana, helped India seize the momentum…